Cargando…
Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype
BACKGROUND: Low high‐density lipoprotein (HDL) levels are major predictors of cardiovascular (CV) events, even in patients on statin treatment with low‐density lipoprotein (LDL) at target. In animal models HDLs protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whet...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647282/ https://www.ncbi.nlm.nih.gov/pubmed/23557750 http://dx.doi.org/10.1161/JAHA.113.000063 |
_version_ | 1782268709457362944 |
---|---|
author | Vazzana, Natale Ganci, Antonina Cefalù, Angelo Baldassare Lattanzio, Stefano Noto, Davide Santoro, Nicole Saggini, Raoul Puccetti, Luca Averna, Maurizio Davì, Giovanni |
author_facet | Vazzana, Natale Ganci, Antonina Cefalù, Angelo Baldassare Lattanzio, Stefano Noto, Davide Santoro, Nicole Saggini, Raoul Puccetti, Luca Averna, Maurizio Davì, Giovanni |
author_sort | Vazzana, Natale |
collection | PubMed |
description | BACKGROUND: Low high‐density lipoprotein (HDL) levels are major predictors of cardiovascular (CV) events, even in patients on statin treatment with low‐density lipoprotein (LDL) at target. In animal models HDLs protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whether HDL levels are related to in vivo oxidative stress and platelet activation, as determinants of atherothrombosis. METHODS AND RESULTS: Urinary 8‐iso‐PGF(2α) and 11‐dehydro‐TXB(2), in vivo markers of oxidative stress and platelet activation, respectively, were measured in 65 coronary heart disease (CHD) normocholesterolemic patients with HDL ≤35 mg/dL, and in 47 CHD patients with HDL >35 mg/dL. The 2 eicosanoids were also measured before and after an intensive exercise program in sedentary people (n=18) and before and after fenofibrate treatment in otherwise healthy subjects with low HDL (n=10). Patients with HDL ≤35 mg/dL showed significantly higher urinary 8‐iso‐PGF(2α) (median [25th to 75th percentiles]: 289 [189 to 380] versus 216 [171 to 321] pg/mg creatinine, P=0.019) and 11‐dehydro‐TXB(2) (563 [421 to 767] versus 372 [249 to 465] pg/mg creatinine, P=0.0001) than patients with higher HDL. A direct correlation was found between urinary 8‐iso‐PGF(2α) and 11‐dehydro‐TXB(2) in the entire group of patients (ρ=0.77, P<0.0001). HDL levels were inversely related to both 8‐iso‐PGF(2α) (ρ=−0.32, P=0.001) and 11‐dehydro‐TXB(2) (ρ=−0.52, P<0.0001). On multiple regression, only 8‐iso‐PGF(2α) (β=0.68, P<0.0001) and HDL level (β=−0.29, P<0.0001) were associated with urinary 11‐dehydro‐TXB(2) excretion, independent of sex, age, smoking, hypertension, diabetes, previous myocardial infarction, total cholesterol, LDL, and triglycerides. Both intensive exercise and fenofibrate treatment significantly reduced the 2 eicosanoids in healthy subjects, in parallel with an HDL increase. CONCLUSIONS: A low HDL phenotype, both in CHD patients and in healthy subjects, is associated with increased lipid peroxidation and platelet activation. These data provide novel insight into the mechanisms linking low HDL with increased CV risk. |
format | Online Article Text |
id | pubmed-3647282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-36472822013-05-08 Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype Vazzana, Natale Ganci, Antonina Cefalù, Angelo Baldassare Lattanzio, Stefano Noto, Davide Santoro, Nicole Saggini, Raoul Puccetti, Luca Averna, Maurizio Davì, Giovanni J Am Heart Assoc Original Research BACKGROUND: Low high‐density lipoprotein (HDL) levels are major predictors of cardiovascular (CV) events, even in patients on statin treatment with low‐density lipoprotein (LDL) at target. In animal models HDLs protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whether HDL levels are related to in vivo oxidative stress and platelet activation, as determinants of atherothrombosis. METHODS AND RESULTS: Urinary 8‐iso‐PGF(2α) and 11‐dehydro‐TXB(2), in vivo markers of oxidative stress and platelet activation, respectively, were measured in 65 coronary heart disease (CHD) normocholesterolemic patients with HDL ≤35 mg/dL, and in 47 CHD patients with HDL >35 mg/dL. The 2 eicosanoids were also measured before and after an intensive exercise program in sedentary people (n=18) and before and after fenofibrate treatment in otherwise healthy subjects with low HDL (n=10). Patients with HDL ≤35 mg/dL showed significantly higher urinary 8‐iso‐PGF(2α) (median [25th to 75th percentiles]: 289 [189 to 380] versus 216 [171 to 321] pg/mg creatinine, P=0.019) and 11‐dehydro‐TXB(2) (563 [421 to 767] versus 372 [249 to 465] pg/mg creatinine, P=0.0001) than patients with higher HDL. A direct correlation was found between urinary 8‐iso‐PGF(2α) and 11‐dehydro‐TXB(2) in the entire group of patients (ρ=0.77, P<0.0001). HDL levels were inversely related to both 8‐iso‐PGF(2α) (ρ=−0.32, P=0.001) and 11‐dehydro‐TXB(2) (ρ=−0.52, P<0.0001). On multiple regression, only 8‐iso‐PGF(2α) (β=0.68, P<0.0001) and HDL level (β=−0.29, P<0.0001) were associated with urinary 11‐dehydro‐TXB(2) excretion, independent of sex, age, smoking, hypertension, diabetes, previous myocardial infarction, total cholesterol, LDL, and triglycerides. Both intensive exercise and fenofibrate treatment significantly reduced the 2 eicosanoids in healthy subjects, in parallel with an HDL increase. CONCLUSIONS: A low HDL phenotype, both in CHD patients and in healthy subjects, is associated with increased lipid peroxidation and platelet activation. These data provide novel insight into the mechanisms linking low HDL with increased CV risk. Blackwell Publishing Ltd 2013-04-24 /pmc/articles/PMC3647282/ /pubmed/23557750 http://dx.doi.org/10.1161/JAHA.113.000063 Text en © 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley-Blackwell. http://creativecommons.org/licenses/by/2.5/ This is an Open Access article under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Vazzana, Natale Ganci, Antonina Cefalù, Angelo Baldassare Lattanzio, Stefano Noto, Davide Santoro, Nicole Saggini, Raoul Puccetti, Luca Averna, Maurizio Davì, Giovanni Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype |
title | Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype |
title_full | Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype |
title_fullStr | Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype |
title_full_unstemmed | Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype |
title_short | Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low‐HDL Phenotype |
title_sort | enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low‐hdl phenotype |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647282/ https://www.ncbi.nlm.nih.gov/pubmed/23557750 http://dx.doi.org/10.1161/JAHA.113.000063 |
work_keys_str_mv | AT vazzananatale enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype AT ganciantonina enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype AT cefaluangelobaldassare enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype AT lattanziostefano enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype AT notodavide enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype AT santoronicole enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype AT sagginiraoul enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype AT puccettiluca enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype AT avernamaurizio enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype AT davigiovanni enhancedlipidperoxidationandplateletactivationaspotentialcontributorstoincreasedcardiovascularriskinthelowhdlphenotype |